Chabot JA et al., 2010-04-20: NCI-sponsored trial that began as a randomised phase 3 comparison of proteolytic enzyme therapy versus gemcitabine in inoperable pancreatic cancer but became observational when most eligible patients refused random assignment. Of 55 patients, the 23 who chose chemotherapy survived a median 14 months versus 4.3 months for the 32 who chose enzyme treatment, with better quality of life on chemotherapy.
Kaplan-Meier analysis found a 9.7-month difference in median survival between the chemotherapy group (median survival, 14 months) and enzyme treatment groups (median survival, 4.3 months)
p.2058 (Abstract, Results)
Chabot JA et al., 2010-04-20: NCI-sponsored trial that began as a randomised phase 3 comparison of proteolytic enzyme therapy versus gemcitabine in inoperable pancreatic cancer but became observational when most eligible patients refused random assignment. Of 55 patients, the 23 who chose chemotherapy survived a median 14 months versus 4.3 months for the 32 who chose enzyme treatment, with better quality of life on chemotherapy. Funder: the National Cancer Institute sponsored the trial (per the abstract); the authors' disclosures sit at the end of the article and were not captured. Comparator: gemcitabine-based chemotherapy (Eli Lilly's Gemzar), not placebo; the enzyme arm was the Gonzalez regimen (pancreatic enzymes, nutritional supplements, detoxification, organic diet). Design fact the book must not omit: only three patients agreed to random assignment in 14 months, so the published comparison is self-selected and non-randomised – see CHD-24 and CHD-25. Study type: controlled study.
